TABLE 3

Proposed Reading and Interpretation Criteria by PSMA RADS (56), E-PSMA (66), and PROMISE (55) for PSMA PET

ParameterPSMA RADS (65)E-PSMA (66)PROMISE (64)
PSMA PET reading scoreE-PSMA scores*: 0–3; 0: uptake < blood pool; 1: uptake > blood pool and < liver; 2: uptake > liver and < parotid glands; 3: uptake > parotid glandsmiPSMA scores: 0–3; 0: uptake < blood pool; 1: uptake > blood pool and < liver; 2: uptake > liver and < parotid glands; 3: uptake > parotid glands
PSMA PET interpretation1A: benign lesion without abnormal uptake; 1B: benign lesion with abnormal uptake; 2: likely benign; 3: equivocal; 3A: equivocal uptake in soft-tissue site typical of PCa involvement; 3B: equivocal uptake in bone lesion not definitive but also not atypical of PCa on anatomic imaging; 3C: intense uptake in site highly atypical of all but advanced stages of PCa; 3D: lesion suggestive of malignancy on anatomic imaging but lacking uptake; 4: PCa highly likely, with intense uptake in site typical of PCa but lacking definitive findings on conventional imaging; 5: PCa almost certainly present1: benign lesion without abnormal PSMA uptake; 2: probably benign lesion, with faint PSMA uptake in site atypical of PCa; 3: equivocal finding, with faint uptake in site typical of PCa or intense uptake in site atypical of PCa; 4: probably PCa, with intense uptake in site typical of PCa but without definitive findings on CT; 5: definitive evidence of PCa, with intense uptake in site typical of PCa and definitive findings on CTScores 2 and 3 should be considered PCa lesions, depending on clinical context, extent, and location of findings
  • * Designed for most extensively used PSMA ligands (68Ga-PSMA-11, 18F-DCFPyL, and 18F-PSMA-1007).

  • Designed mainly for 68Ga-PSMA-11. For PSMA ligands with liver-dominant excretion, spleen is recommended as reference organ instead of liver.